引用次数
引用: 63,129
H-指数: 101
I10-指数 : 366
出版物: 915
272 LAPAROSCOPIC ADRENALECTOMY FOR METASTASIS OF LUNG CANCER: REVIEW OF OUR EXPERIENCE
F. Porpiqlia , J. Renard , M. Billia , A. Volpe
European Urology Supplements 6 ( 2) 90
2007
ROLE OF LAPAROSCOPIC ADRENALECTOMY FOR THE MANAGEMENT OF METASTASIS IN ADVANCED LUNG CANCER
F. Porpiglia , M. Billia , M. Selvaggi , P. Novello
European Urology Supplements 7 ( 3) 194
2008
A Large Retrospective Analysis of Pemetrexed (PEM) Activity in Patients (PTS) with Alk-Positive (Alk+) Non-Small Cell Lung Cancer (NSCLC) Prior to Crizotinib (CRIZ) Treatment
G. Scagliotti , D.W. Kim , A.T. Shaw , S.I. Ou
Annals of Oncology 23
1
2012
An Exploratory Phase 2 Study of Pemetrexed (Pem) and Cisplatin (Cis) As Preoperative Chemotherapy (Ct) in the Treatment of Stage Iiian2 Nonsquamous Non-Small Cell Lung Cancer (Ns Nsclc)
U. Pastorino , M. Platania , F. Rea , M. Schiavon
Annals of Oncology 25 iv420
2014
Two Phase III Studies Evaluating Ceritinib in Patients (Pts) with Anaplastic Lymphoma Kinase (Alk)-Rearranged (Alk+) Non-Small Cell Lung Cancer (Nsclc): Ascend-4 and Ascend-5
A. Shaw , D.S.W. Tan , L. Crinò , E. Felip
Annals of Oncology 25 iv469
4
2014
A Randomized Phase III Multicenter Trial of Customized Chemotherapy Versus Standard of Care for 1St Line Treatment of Elderly Patients with Advanced Non-Small-Cell Lung Cancer (Nsclc): the Elderly Patient Individualized Chemotherapy (Epic) Trial
T. Vavala , S. Novello , F. Grossi , A. Misino
Annals of Oncology 25 iv467
2014
Outcomes of Elderly Patients (≥70 Yo) with Advanced Non-Small Cell Lung Cancer (Nsclc): a Multi-Institutional Analysis
N. Tariq , V. Bertaglia , N. Shah , T. Mele
Annals of Oncology 25 iv442
2014
A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer
S. Novello , B. Besse , E. Felip , F. Barlesi
Annals of Oncology 25 ( 11) 2156 -2162
20
2014
Efficacy of zoledronic acid for the prevention of bone metastases in patients with non-small cell lung cancer
G. Scagliotti , C. Manegold , P. Kosmidis , A. Kirner
Bone 38 ( 3) 83
2
2006
Combination Chemotherapy and Interferon α2b in the Treatment of Advanced Non-Small-Cell Lung Cancer
A. Ardizzoni , R. Rosso , F. Salvati , G. Scagliotti
American Journal of Clinical Oncology 14 ( 2) 120 -123
12
1991
793 Multicenter phase II study of gemcitabine-oxaliplatin (GEMOX) chemotherapy in untreated locally advanced or metastatic non-small cell lung cancer (NSCLC) patients
F. Cappuzzo , S. Novello , F. De Marinis , M. Maur
Ejc Supplements 1 ( 5)
1
2003
Comparison of pemetrexed plus cisplatin with other first-line doublets in advanced non-small cell lung cancer (NSCLC): A combined analysis of three phase III trials.
J. Treat , G. Scagliotti , G. Peng , M. J. Monberg
Journal of Clinical Oncology 29
1
2011
A phase III, randomized, double-blind, placebo-controlled study of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated subjects with locally advanced or metastatic, nonsquamous, non-small cell lung cancer (NSCLC) .
A. Sandler , J. H. Schiller , V. Hirsh , L. V. Sequist
Journal of Clinical Oncology 29
9
2011
An international, randomized, placebo-controlled, double-blind phase III study (MONET1) of motesanib plus carboplatin/paclitaxel (C/P) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC).
G. Scagliotti , I. Vynnychenko , Y. Ichinose , K. Park
Journal of Clinical Oncology 29
25
2011
PL02.09 Nintedanib + Pemetrexed/Cisplatin in Patients with Unresectable MPM: Phase III Results from the LUME-Meso Trial
G. Scagliotti , R. Gaafar , A. Nowak , T. Nakano
Journal of Thoracic Oncology 13 ( 10)
5
2018
MA 07.14 Change in Practice Patterns from an Online NSCLC Treatment Decision Support Tool
D.R. Gandara , R. Herbst , T. Mok , S. Ramalingam
Journal of Thoracic Oncology 12 ( 11)
2017
MA 19.03 Nintedanib + Pemetrexed/Cisplatin in Malignant Pleural Mesothelioma (MPM): Phase II Biomarker Data from the LUME-Meso Study
A. Nowak , F. Grosso , N. Steele , S. Novello
Journal of Thoracic Oncology 12 ( 11)
4
2017
P1.09-011 LUME-Meso Phase II/III Study: Nintedanib + Pemetrexed/Cisplatin in Chemo-Naïve Patients with Malignant Pleural Mesothelioma
A. Tsao , N. Vogelzang , A. Nowak , S. Popat
Journal of Thoracic Oncology 12 ( 11) S2021 -S2022
2017
OA03.06 Overall Survival and Forced Vital Capacity in the LUME-Meso Study of Nintedanib + Pemetrexed/Cisplatin in Patients with Mesothelioma: Topic: Medical Oncology
S. Novello , A. Nowak , F. Grosso , N. Steele
Journal of Thoracic Oncology 12 ( 11)
2017
P2.09-003 Dissecting the Immune Environment in Malignant Pleural Mesothelioma: Results from a Prospective Assessment
C. Riganti , M. Pradotto , L. Righi , C. Marchiò
Journal of Thoracic Oncology 12 ( 11) S2157
2017